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Abstract 
 
We report the case of a rare, benign mesenchymal tumour arising from the cervix. A 53-year-old post-menopausal 
woman presented with mass per vagina. Examination revealed stage 2 utero-vaginal prolapse and multiple elongated 
polyps seen at the cervix. She underwent local excision. Histopathological examination findings and the 
immunohistochemical studies were consistent with Angiomyofibroblastoma. 
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Introduction 
 
Angiomyofibroblastoma (AMFB) is a unique clinical 
entity that exhibits myofibroblastic differentiation and 
stromal cell proliferation (1). Despite the fact that it 
has been recognized for the past few decades, the 
cause is still not well defined. It is a rare, benign, 
mesenchymal tumour and commonly involves female 
lower genital tract i.e. vulva, vagina and labia majora 
(2). Cervical AMFB is even rarer. To date, only two 
cases have been reported (3,4). We report a case of 
cervical AMFB and illustrate the importance of 
recognition of this entity with accurate pre-operative 
diagnosis. 
 
Case Report 
 
A 53-year-old post-menopausal woman, Para 2+1, 
complained of mass per vaginal which was affecting 
her daily activity and sexual life. There was no vaginal 
bleeding, abnormal discharge, urinary or bowel 
symptoms. She was rather healthy except for well-
controlled diabetes mellitus and hypertension. Physical 
examination demonstrated a stage 2 utero-vaginal 
prolapse (UVP). There were multiple elongated polyps 
seen at the cervix (Fig. 1). The largest polyp measured 
4x3 cm in diameter. The polyps were excised and sent 
for histopathological examination. She was counselled 
that the choices of treatment option for her UVP would 
depend on the histopathological finding of the cervical 
polyps.  
 
Histopathological examination (HPE) revealed 
polypoidal tissues lined by stratified squamous 
epithelium and were composed of hyper and 
hypocellular areas admixed with small blood vessel. 
There were spindle and plump stromal cells 
aggregated around the vessels (Fig. 2). A focal area of 
marked neutrophils and lymphocytes infiltrate within 
the stroma was seen. There was no evidence of 
malignancy. The immunohistochemical studies 
showed the tumour cells were positive for Smooth 
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Muscle Actin (SMA), Desmin and CD34 (Fig. 2) 
which were consistent with angiomyofibroblastoma. 
 
In view of the benign entity, she was given the option 
of vaginal ring and surgical intervention. She had an 
uneventful laparoscopic assisted vaginal hysterectomy 
and bilateral salphingo-oopherectomy, anterior and 
posterior colporrhaphy. Histopathological examination 
of the uterus and both ovaries revealed no evidence of 
endometrial hyperplasia or malignancy. The cervix 
showed few Nabothian cysts with no residual polyp. 
There was no evidence of dysplasia or malignancy. 
She remained asymptomatic with no recurrence of 
either angiomyofibroblastoma or pelvic organ prolapse 
at two-year follow up. 
 
Discussion 
 
Angiomyofibroblastoma was first reported by Fletcher 
et al. almost two decades ago (5). Following that, 
several reports had been published where majority was 
vulvo-vaginal origin (2,6,7). Other rare locations 
include pouch of Douglas (1) and spermatic cord in 
male (8). Kitamura et al. (9) reported another 
interesting case: a young 24-year-old lady presented 
with abnormal posteriorly directed urinary jet due to 
urethral AMFB. Angiomyofibroblastoma during 
pregnancy had been reported as well (10). 
 
Vulvo-vaginal AMFB is easily detectable due to its 
location. However, AMFB arising from other regions 
such as pouch of Douglas, may present with huge 
pelvic mass and pose significant challenge to establish 
the diagnosis (1). In the present case, the polypoidal 
growth was easily seen due to the stage 2 UVP. 
Angiomyofibroblastoma of the cervix is extremely 
uncommon with only two published reports so far 
(Table 1) (3,4). Therefore, AMFB of the cervix is 
rarely being considered pre-operatively. Both reported 
 
 
 
Figure 1: Multiple elongated polyps seen at cervix
 
 
Figure 2: a) Polypoidal tissue lined by squamous epithelium (H&E, 2x) b) Hypocellular and hypercellular area admixed with 
small blood vessels (H&E, 4x)  c) Spindle cells aggregate around blood vessels (H&E, 40x)  d) Tumour cells immunopositive for: 
i) Smooth Muscle Actin (SMA, 40x),  ii) Desmin (40x),  iii) CD34 (40x) 
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Table 1: Cervical angiomyofibroblastoma reported in the literature. 
Case Age (years) Presentation Size (cm) Positive IHC Negative IHC Treatment Reference 
1 43 asymptomatic 
cervical myoma 
3.0x3.0x2.5 vimentin, 
desmin 
actin, CD34 local 
excision 
Kim et al. 
2011 [3] 
2 44 polypoidtumour 2.0 
 
vimentin, 
desmin,CD44 
sarkomeric actin, 
Ki67 
N/A Babala et al 
2011 [4] 
3 53 vaginal mass 4.0x3.0 SMA, desmin, 
CD34 
N/A 
 
local 
excision 
Present case 
IHC: Immunohistochemistry 
N/A: Not available 
 
cases presented with asymptomatic mass per vaginal at 
their fifth decade of life. In fact, one of these cases 
underwent local excision for suspected cervical 
myoma, with AMFB diagnosed only after HPE.  
 
Total excision, which is curative, is the treatment for 
cervical AMFB. There was only one case being 
reported to have tumour recurrence (11) and the 
excised recurrent tumour was confirmed to be benign 
in nature.  
 
Although, almost all reported cases in the literature 
showed that AMFB exhibited benign course, there was 
a case of vulva AMFB that underwent sarcomatous 
transformation (12). In addition, aggressive 
angiomyxoma (AA), a form of locally invasive 
malignant mesenchymal tumours, shares many 
common features with AMFB including presentation 
and pathological entities. It has high tendency to recur 
even years after resection (13).  
 
When compared to AMFB, AA tends to be larger (up 
to 60cm) macroscopically, where as AMFB is smaller 
and measures average 4cm in size (0.5-12cm) (5,13). 
Microscopically, AA displays sparse cellularity with 
stellate cells widely separated by loose myxoid stroma, 
where as AMFB demonstrates alternating 
hypercellular and hypocellular zones with irregularly 
distributed blood vessels which was observed in our 
case. Immunostaining pattern towards SMA, desmin 
and CD34 may be helpful, however, there are variable 
overlapping features in both AA and AMFB. There is 
emerging potential marker like HMGA2 protein 
expression that could help in differentiating AA from 
AMFB. Aberrant nuclear HMGA2 expression was 
found in 1/3 of cases of AA but not in AMFB (14).  
 
Therefore, a more aggressive approach might be 
needed if AA is suspected. Hence in the presence case, 
our pathologist took great effort to exclude possibility 
of AA, including use of immunohistochemical 
staining, in order to assist us in formulating the 
management plan for the stage 2 UVP. 
Conclusion 
 
Cervical AMFB is extremely rare. Recognition of this 
unique clinical entity pre-operatively is important for 
surgical planning as it shows benign characteristics 
compared to other malignant tumour like AA. 
Furthermore, patient’s counseling is of paramount 
important particularly when patient is having 
concurrent UVP. 
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